Quidel Corporation (NASDAQ: QDEL) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitabiliy, risk, institutional ownership, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings for Quidel Corporation and IDEXX Laboratories, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quidel Corporation 0 3 2 0 2.40
IDEXX Laboratories 2 2 2 0 2.00

Quidel Corporation currently has a consensus price target of $23.88, indicating a potential downside of 7.25%. IDEXX Laboratories has a consensus price target of $161.00, indicating a potential downside of 0.19%. Given IDEXX Laboratories’ higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than Quidel Corporation.

Valuation & Earnings

This table compares Quidel Corporation and IDEXX Laboratories’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Quidel Corporation $214.97 million 3.98 $39.80 million $0.10 257.43
IDEXX Laboratories $1.82 billion 7.81 $449.79 million $2.71 59.52

IDEXX Laboratories has higher revenue and earnings than Quidel Corporation. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Quidel Corporation, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

89.6% of Quidel Corporation shares are owned by institutional investors. Comparatively, 89.1% of IDEXX Laboratories shares are owned by institutional investors. 22.0% of Quidel Corporation shares are owned by insiders. Comparatively, 2.8% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Quidel Corporation and IDEXX Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quidel Corporation 1.83% 1.94% 1.02%
IDEXX Laboratories 13.47% -706.91% 15.74%

Risk & Volatility

Quidel Corporation has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Summary

IDEXX Laboratories beats Quidel Corporation on 7 of the 13 factors compared between the two stocks.

Quidel Corporation Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.